Steele Christopher Eugene 4

What Happened
Christopher Eugene Steele, listed in the filing as a Director with remarks identifying him as Chief Clinical Officer - General Practices, was granted 5,855 restricted stock units (RSUs) on June 15, 2026. The grant is reported as an award (transaction code A) with an acquisition price of $0.00 (no cash paid). The RSUs are derivative awards that convert into common shares upon vesting.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-22 (filed 7 days after the grant; appears late compared with the usual 2-business-day Form 4 deadline).
• Grant: 5,855 RSUs; reported price $0.00; total cash consideration reported $0.
• Vesting: 25% vest on each of the first four anniversaries of the grant date, subject to continued service and award terms (footnote).
• Shares owned after transaction: not specified in this filing.
• Footnotes: F1 = 1 RSU = contingent right to 1 share upon vesting; F2 = four-year, 25% annual vesting schedule; F3 = granted for no cash consideration.

Context
This was an equity award (RSUs), not an open-market purchase or sale. RSU grants are common compensation for executives and do not by themselves indicate buying or selling sentiment — value is realized only as units vest and convert to shares. The late filing may be noteworthy for compliance monitoring but does not change the nature of the award.